FDA Zaps Tongue Nerve Stimulators into Moderate Regulation Category
Published Date: 12/19/2025
Rule
Summary
The FDA is officially classifying the electrical tongue nerve stimulator, a device that helps people with movement problems, as a Class II device with special safety rules. This change makes it easier and faster for patients to get this innovative treatment by reducing some regulatory hurdles. The new classification is effective December 19, 2025, and could speed up device availability without extra costs for users.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Class II ruling speeds patient access
The FDA classified the electrical tongue nerve stimulator as a Class II device with special controls, which the agency says will enhance patients' access and reduce regulatory burdens. The final order is effective December 19, 2025, and FDA states this classification can make it easier and faster for patients to get this treatment.
Creates predicate for future devices
Because FDA classified this device via the De Novo process, the electrical tongue nerve stimulator can serve as a predicate device. Future device sponsors can use the less-burdensome 510(k) process instead of a De Novo request or premarket approval, lowering regulatory hurdles for companies making similar devices.
Manufacturers must meet special controls
To be classified as Class II, manufacturers must meet special controls including biocompatibility testing for patient-contacting components; electromagnetic, battery, electrical, mechanical, and thermal safety testing; non-clinical performance testing of stimulation parameters; software verification/validation and cybersecurity assessment; and specific labeling (technical summary, instructions, cleaning, storage, charging, disposal).
Device is prescription-only
The FDA states the electrical tongue nerve stimulator is a prescription device. That means the device is available only with a prescription and is exempt from layperson 'adequate directions for use' requirements under specified statutory provisions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-23412 — Safety Zone; Fireworks Display, Ohio River Mile Marker 73 to 74, Wellsburg, WV
The Coast Guard is setting up a temporary safety zone on the Ohio River near Wellsburg, WV, from 11 p.m. on December 31, 2025, to 1 a.m. on January 1, 2026, to keep everyone safe during the New Year's Eve fireworks show. Boats and people can’t enter this area unless they get special permission. This quick action helps prevent accidents from fireworks and keeps the river safe without causing delays or costs.
Next: 2025-23414 — Falsification, Reproduction, Alteration, Omission, or Incorrect Statements
The FAA fixed a rule mix-up that accidentally deleted whole sections instead of just small parts about lying or messing with official aviation documents. This fix puts those sections back where they belong, affecting airlines, flight schools, and commercial space operators. The corrected rules take effect December 19, 2025, so everyone should update their records to avoid trouble.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in